Acalabrutinib vs Pirtobrutinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Mantle Cell Lymphoma

Shared mechanism: BTK · full Mantle Cell Lymphoma pipeline

Acalabrutinib

Marketed by AstraZeneca

Approved in Mantle Cell Lymphomasmall molecule (BTK inhibitor)
Weak signal

NCT02213926 · Phase 2 · active, not recruiting

This was a single-arm, open-label study without randomization, blinding, or a comparator. Although the clinical response endpoint was reported in 124 participants, a comparative treatment effect could not be tested, so the evidence is limited.

Next expected readout: December 2026 · NCT04115631 (registry estimate)

Reported efficacy

Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants (not_applicable)

Result source: NCT02213926

Pirtobrutinib

Marketed by Eli Lilly

Approved in Mantle Cell Lymphomasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT06522386 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Mantle Cell Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Pirtobrutinib: no structured comparison results are available for Mantle Cell Lymphoma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Acalabrutinib
Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants NCT02213926 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Chronic Lymphocytic Leukemia

Shared mechanism: BTK · full Chronic Lymphocytic Leukemia pipeline

Acalabrutinib

Marketed by AstraZeneca

Approved in Chronic Lymphocytic Leukemiasmall molecule (BTK inhibitor)
Partial signal

NCT02475681 · Phase 3 · completed

This was a randomized phase 3 trial of 535 people with an active comparator and a hard progression-free survival endpoint that was clearly met. Only outcome assessors were masked and treatment was open-label, so it is graded below the highest tier.

Next expected readout: December 2026 · NCT05971251 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Acalabrutinib 38.4 Months (95% CI 33 to 38.6) | Ibrutinib 38.4 Months (95% CI 33 to 41.6) (met)

Result source: NCT02477696

Pirtobrutinib

Marketed by Eli Lilly

Approved in Chronic Lymphocytic Leukemiasmall molecule
Partial signal

NCT04666038 · Phase 3 · active, not recruiting

Patients were randomised 1:1 against active standard options and the primary endpoint, independently assessed progression-free survival, was met (hazard ratio 0.536, p=0.0002) in 238 patients. The trial was open-label, so patients and clinicians knew the assigned treatment, and the comparator was a mix of two regimens with crossover allowed after progression.

Next expected readout: December 2026 · NCT06466122 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) (Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)): Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) (Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)): Arm A - Pirtobrutinib 13.96 Months (95% CI 11.24 to 16.56) | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab 8.74 Months (95% CI 8.08 to 10.38) (met)

Result source: NCT04666038

Results for Chronic Lymphocytic Leukemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Acalabrutinib: registry results are on file for Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.

Pirtobrutinib: registry results are on file for Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.

Relapsed/Refractory Chronic Lymphocytic Leukemia

Shared mechanism: BTK · full Relapsed/Refractory Chronic Lymphocytic Leukemia pipeline

Acalabrutinib

Marketed by AstraZeneca

Approved in Relapsed/Refractory Chronic Lymphocytic Leukemiasmall molecule (BTK inhibitor)
Partial signal

NCT02970318 · Phase 3 · active, not recruiting

This was a randomized phase 3 trial of 310 people against an active comparator with a hard progression-free survival endpoint that was clearly met. Treatment was open-label with only outcome assessors masked, so it is graded below the highest tier.

Next expected readout: March 2028 · NCT04560322 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Acalabrutinib 38.4 Months (95% CI 33 to 38.6) | Ibrutinib 38.4 Months (95% CI 33 to 41.6) (met)

Result source: NCT02477696

Pirtobrutinib

Marketed by Eli Lilly

Approved in Relapsed/Refractory Chronic Lymphocytic Leukemiasmall molecule
Partial signal

NCT04666038 · Phase 3 · active, not recruiting

Patients were randomised 1:1 against active standard options and the primary endpoint, independently assessed progression-free survival, was met (hazard ratio 0.536, p=0.0002) in 238 patients. The trial was open-label, so patients and clinicians knew the assigned treatment, and the comparator was a mix of two regimens with crossover allowed after progression.

Next expected readout: December 2027 · NCT04623541 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) (Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)): Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) (Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)): Arm A - Pirtobrutinib 13.96 Months (95% CI 11.24 to 16.56) | Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab 8.74 Months (95% CI 8.08 to 10.38) (met)

Result source: NCT04666038

Results for Relapsed/Refractory Chronic Lymphocytic Leukemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Acalabrutinib: registry results are on file for Relapsed/Refractory Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.

Pirtobrutinib: registry results are on file for Relapsed/Refractory Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acalabrutinib's landscape · Pirtobrutinib's landscape